What to check before a study guides your care

What to check on your X-ray

Most of the hopeful research involved knees with mild or moderate wear. It didn't show that badly worn, bone-on-bone joints would get the same relief.

Ask the doctor to point out the worn area on your X-ray. You'll need to know whether the study included joints worn much like yours.

A hip or shoulder isn't simply another knee. Results from one joint can't settle what will happen in a different joint.

What warning signs need prompt care

Heat, heavy swelling, and fever may call for care that day. Don't wait if the joint looks bent, locks after a sudden hurt, or won't hold your weight.

Sudden weak muscles, numb skin, or lost bladder or bowel control also need prompt help. Those signs can come from pressure on nerves in the back, even when the sore leg or weak muscles made the trouble seem like a joint problem when it began.

Call a doctor if warmth or redness spreads after a shot or operation on the joint. That isn't ordinary soreness to watch at home.

What to do when home care isn't enough

At QC Kinetix, joint preservation means care discussed before knee or hip surgery, when the exam supports it. Its regenerative options can include a non-surgical shot made with blood prepared during the visit for soreness due to arthritis or a tendon problem.

For PRP, blood is drawn and spun so platelets gather in the liquid used for the shot. A medical provider, the clinician who checks you, will explain whether that care fits or other care makes more sense.

Bring your X-ray, medicine names, and a short note about sleep, walking, and chores. You won't have to recall every detail while you're being examined.

Sources

1. The ESSKA-ORBIT European consensus on blood-derived orthobiologics graded 28 question-statement sets; only 9 of 28 had high-level scientific support. Three statements reached grade A: that there is enough preclinical and clinical evidence to support PRP use in knee OA; that clinical evidence shows effectiveness in MILD TO MODERATE knee OA (KL grade 3 or lower); and that PRP provides a longer effect than the short-term effect of corticosteroid with a safer profile. The panel regarded PRP as a valid and possible first-line injectable option for KL grades 1-3.

   Laver L, et al. — The use of injectable orthobiologics for knee osteoarthritis: A European ESSKA-ORBIT consensus. Part 1-Blood-derived products (platelet-rich plasma).. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12077.

2. A network meta-analysis of 11 RCTs (1,353 patients) with HIP osteoarthritis found that at 2-4 and 6 months NO intervention - corticosteroid, hyaluronic acid or PRP - significantly outperformed intra-articular saline placebo for either pain or function, while all interventions including placebo produced improvement exceeding the minimal clinically important difference from baseline. Evidence from the knee does not transfer to the hip.

   Gazendam A, et al. — Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials.. British Journal of Sports Medicine, 2021. DOI: 10.1136/bjsports-2020-102179.

3. A meta-analysis of 6 RCTs (860 patients, 334 receiving BMAC) found overall complication rates of 41.91% for BMAC versus 41.25% for comparator injectables (P=0.85), with knee effusion the commonest BMAC complication at 18.26%. Early and late complication rates did not differ significantly from HA, steroids, PRP, SVF, MSC or saline. The number needed to harm for BMAC relative to other injections was 152.

   Fucaloro S, et al. — Complication rates of bone marrow aspirate concentrate injections versus other injectable therapies for knee osteoarthritis: A systematic review and meta-analysis.. Journal of Orthopaedics, 2025. DOI: 10.1016/j.jor.2024.10.005.

4. A phase I/II randomized trial (n=26) compared hyaluronic acid with a single or a repeated dose of culture-expanded umbilical cord-derived MSCs. Only the MSC-treated patients improved significantly from baseline, and the repeated-dose group had significantly lower WOMAC pain (1.1 vs 4.3; P=.04) and VAS pain (2.4 vs 22.1; P=.03) than HA at 12 months. No MRI differences were detected and the trial is very small - it is hypothesis-generating, not practice-changing.

   Matas J, et al. — Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial.. Stem Cells Translational Medicine, 2019. DOI: 10.1002/sctm.18-0053.

5. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.